Featured Research

from universities, journals, and other organizations

How TB 'Develops Invincibility' Against Only Available Treatment

Date:
March 18, 2008
Source:
University of Leicester
Summary:
Scientists have uncovered a dramatic new twist in the battle against TB. They have identified how the killer bacterium makes itself immune to a key component of the only effective treatment against the disease.

Isoniazid bound to activating enzyme.
Credit: Image courtesy of University of Leicester

Scientists at the University of Leicester have uncovered a dramatic new twist in the battle against TB.

They have identified how the killer bacterium makes itself immune to a key component of the only effective treatment against the disease.

Earlier this month, a separate team of TB researchers at Leicester announced a new advance in their fight against the resurgence of TB in Britain. They isolated the molecular 'weapons' of the bacterium and are assessing ways to make the bacterium impotent.

Now, in new research published in the Journal of Biological Chemistry, another team from the Departments of Biochemistry and Chemistry at the University has shown how the TB bacteria becomes resistant to one of the only available treatments for the killer disease.

Dr Peter Moody of the Biochemistry Department said: "Isoniazid is a pro-drug that an enzyme in the deadly bacteria itself makes active.

"Using the technique of protein crystallography and the incredibly bright X-ray source of the European Synchrotron at Grenoble, my team and that of Professor Emma Raven of the Chemistry Department at Leicester along with Dr Katherine Brown of Imperial College have shown how the pro-drug binds to two very similar enzymes - and from this we can see how mutations in the bacterial enzyme protect it from the treatment."

This is the first time anyone has seen the way the pro-drug binds to activating enzymes.

Dr Moody said: "Drug-resistant forms of TB are approaching 10% of the 8000 cases a year in the UK, so understanding how this works is very important."

The researchers hope that this new understanding will help drug companies devise treatments for the resistant strains.

Dr Moody added: "Unfortunately, development of the UK synchrotron source (Diamond) is under threat because of the shortfall in funding, which could limit our ability to do this sort of fundamental medical research in the future".

Journal reference: The Tuberculosis Prodrug Isoniazid Bound to Activating Peroxidases. Clive Metcalfe, Isabel K. Macdonald, Emma J. Murphy, Katherine A. Brown, Emma Lloyd Raven, and Peter C. E. Moody J. Biol. Chem., Vol. 283, Issue 10, 6193-6200, March, 2008

The study is funded by BBSRC.


Story Source:

The above story is based on materials provided by University of Leicester. Note: Materials may be edited for content and length.


Cite This Page:

University of Leicester. "How TB 'Develops Invincibility' Against Only Available Treatment." ScienceDaily. ScienceDaily, 18 March 2008. <www.sciencedaily.com/releases/2008/03/080313083035.htm>.
University of Leicester. (2008, March 18). How TB 'Develops Invincibility' Against Only Available Treatment. ScienceDaily. Retrieved September 19, 2014 from www.sciencedaily.com/releases/2008/03/080313083035.htm
University of Leicester. "How TB 'Develops Invincibility' Against Only Available Treatment." ScienceDaily. www.sciencedaily.com/releases/2008/03/080313083035.htm (accessed September 19, 2014).

Share This



More Health & Medicine News

Friday, September 19, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

The Cost of Ebola

The Cost of Ebola

Reuters - Business Video Online (Sep. 18, 2014) As Sierra Leone prepares for a three-day "lockdown" in its latest bid to stem the spread of Ebola, Ciara Lee looks at the financial implications of fighting the largest ever outbreak of the disease. Video provided by Reuters
Powered by NewsLook.com
What HealthKit Bug Means For Your iOS Fitness Apps

What HealthKit Bug Means For Your iOS Fitness Apps

Newsy (Sep. 18, 2014) Apple has delayed the launch of the HealthKit app platform, citing a bug. Video provided by Newsy
Powered by NewsLook.com
U.S. Food Makers Surpass Calorie-Cutting Pledge

U.S. Food Makers Surpass Calorie-Cutting Pledge

Newsy (Sep. 18, 2014) Sixteen large food and beverage companies in the United States that committed to cut calories in their products far surpassed their target. Video provided by Newsy
Powered by NewsLook.com
Residents Vaccinated as Haiti Fights Cholera Epidemic

Residents Vaccinated as Haiti Fights Cholera Epidemic

AFP (Sep. 18, 2014) Haitians receive the second dose of the vaccine against cholera as part of the UN's vaccination campaign. Duration: 00:34 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins